Interferon alfa-2a
- Generic Name
- Interferon alfa-2a
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 76543-88-9
- Unique Ingredient Identifier
- 47RRR83SK7
- Background
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
- Indication
For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, Chronic Myelogenous Leukemia (CML), Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Kaposi's Sarcoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Thrombocytosis
- Associated Therapies
- -
Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 50
- Registration Number
- NCT00226382
- Locations
- ๐จ๐ณ
Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma
- Conditions
- Sarcoma, KaposiHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 60
- Registration Number
- NCT00000687
- Locations
- ๐บ๐ธ
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
๐บ๐ธUniv. of Miami AIDS CRS, Miami, Florida, United States
๐บ๐ธPitt CRS, Pittsburgh, Pennsylvania, United States
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
- Conditions
- HIV InfectionsAnus Neoplasms
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 98
- Registration Number
- NCT00000764
- Locations
- ๐บ๐ธ
University of Washington AIDS CRS, Seattle, Washington, United States
A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 48
- Registration Number
- NCT00000696
- Locations
- ๐บ๐ธ
USC CRS, Los Angeles, California, United States
๐บ๐ธUniv. of Miami AIDS CRS, Miami, Florida, United States
๐บ๐ธTulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans, Louisiana, United States
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 60
- Registration Number
- NCT00000754
- Locations
- ๐บ๐ธ
Alabama Therapeutics CRS, Birmingham, Alabama, United States
๐บ๐ธUniv. of Miami AIDS CRS, Miami, Florida, United States
๐บ๐ธUcsd, Avrc Crs, La Jolla, California, United States
The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 52
- Registration Number
- NCT00000967
- Locations
- ๐ต๐ท
Univ. Hosp. Ramรณn Ruiz Arnau, Dept. of Peds., Bayamon, Puerto Rico
๐บ๐ธSt. Jude/UTHSC CRS, Memphis, Tennessee, United States
๐ต๐ทSan Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
- Conditions
- HIV InfectionsSarcoma, Kaposi
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 56
- Registration Number
- NCT00000725
- Locations
- ๐บ๐ธ
Univ of Miami School of Medicine, Miami, Florida, United States
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
- Conditions
- HIV InfectionsHepatitis C
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 132
- Registration Number
- NCT00008463
- Locations
- ๐บ๐ธ
Ucsf Aids Crs, San Francisco, California, United States
๐บ๐ธThe Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
๐บ๐ธMassachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
- Conditions
- HIV InfectionsSarcoma, Kaposi
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 48
- Registration Number
- NCT00001113
- Locations
- ๐บ๐ธ
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.